Elutia Earnings Call Transcripts
Fiscal Year 2026
-
A drug-eluting biologic platform is being advanced for breast reconstruction, addressing a $1.5 billion U.S. market with high infection rates. The product delivers local antibiotics via mesh, with regulatory approval expected next year and a focused commercialization plan targeting top centers.
-
A proven antibiotic-eluting matrix platform is being adapted for breast reconstruction, targeting a $1.5 billion U.S. market with high infection rates. FDA approvals are expected within a year, with a cost-neutral, high-margin commercialization strategy focused on top hospitals.
-
Q1 2026 saw 6% revenue growth, improved gross margins, and strong liquidity. Regulatory progress and manufacturing advances support confidence in NXT-41x, with FDA clearance and commercialization targeted for 2026–2027. Strategic divestitures are underway.
-
A new drug-eluting biologic for breast reconstruction aims to address a $1.5B market with high infection rates by delivering antibiotics directly at the surgical site. FDA approval for the base matrix is expected this year, with the drug-eluting version targeted for next year.
Fiscal Year 2025
-
Revenue grew 16% year-over-year to $3.3M with improved gross margins and reduced net loss. Strategic sale of BioEnvelope enabled debt repayment and a strong cash position, supporting the focus on NXT-41x for the large breast reconstruction market.
-
Q3 2025 saw the $88M sale of the BioEnvelope business, strengthening the balance sheet and validating the technology. SimpliDerm and Cardiovascular segments showed sequential growth, with improved gross margins and reduced operating expenses. Sufficient cash runway supports NXT-41/41x development and commercialization.
-
A proven drug-eluting biologics platform is being expanded from pacemaker applications to address high infection rates in breast reconstruction, targeting a $1.5 billion market with significant unmet need. The company is fully funded, with FDA filings for its next product expected in 2026.
-
Management highlighted strong commercial traction for EluPro, a drug-eluting biologic for pacemakers, and outlined plans to scale adoption with Boston Scientific's support. The pipeline includes NXT-41X for breast reconstruction, targeting approval in early 2027, while financial strategies aim to extend cash runway and achieve operational leverage.
-
EluPro drove 49% sequential growth and now dominates BioEnvelope revenue, with strong hospital adoption and improved gross margins. NXT-41x breast reconstruction platform is on track for 2026–2027 launches, and legacy litigation is nearly resolved, reducing risk.
-
EluPro's launch drove strong BioEnvelope growth, aided by a major Boston Scientific partnership and expanded manufacturing. Sequential revenue gains, improved margins, and new financing strengthen the outlook, with direct cardiovascular sales and clinical data expected to further boost performance.
-
The presentation highlighted the launch and rapid adoption of a new drug-eluting biologic envelope for pacemakers, supported by a major distribution partnership and strong clinical advantages. Expansion plans include scaling production, growing hospital access, and advancing a promising pipeline for breast reconstruction.
Fiscal Year 2024
-
EluPro's pilot launch drove 18% Q4 growth in device protection sales, with rapid adoption and strong physician support. SimpliDerm grew 12% for the year despite Q4 disruption, and a new Boston Scientific partnership is set to accelerate EluPro's expansion.
-
Q3 2024 saw the first commercial use of EluPro, now 25% of bioenvelope sales, and 19% growth in SimpliDerm. Revenue was $5.9M, with a 61% adjusted gross margin and $25.7M in cash. Full EluPro launch is set for January 2025.
-
EluPro, a new drug-eluting biologic for pacemakers, is launching in January with strong clinical and market advantages, targeting a $600 million market and supported by robust hospital and distributor relationships. SimpliDerm, for breast reconstruction, is also growing rapidly and will soon incorporate drug-eluting technology.
-
EluPro, a first-in-class antibiotic-eluting bioenvelope, is launching into a $600 million US market for pacemaker and defibrillator protection, targeting a large unmet need left by Medtronic’s TYRX. With strong physician interest and a robust financial position, full launch is set for January 2025.
-
Regulatory approval and manufacturing of EluPro mark a pivotal quarter, with strong physician interest and a robust commercial launch plan targeting large cardiac and neurostimulation markets. Financials show stable sales, improved margins, and a strengthened cash position.